1787: Clinical Advancement of a Cancer Vaccine in Dogs

Grant Status: Closed

Grant Amount: $96,660
Nicola J Mason, BVetMed, PhD; University of Pennsylvania
January 1, 2013 - December 31, 2014

Sponsor(s): American Belgian Tervuren Club, Inc., American German Shepherd Dog Charitable Foundation, Inc., American Spaniel Club Foundation, Australian Shepherd Health & Genetics Institute, Canaan Dog Club of America, Cardigan Welsh Corgi Club of America, Clumber Spaniel Health Foundation, Dandie Dinmont Terrier Club of America, Inc., English Setter Association of America, Inc., Flat-Coated Retriever Foundation, Golden Retriever Foundation, Gordon Setter Club of America, Inc., Great Dane Club of America, Irish Wolfhound Club of America, Inc., Mastiff Club of America Charitable Health Trust, National Beagle Club, Newfoundland Club of America Charitable Trust, Old English Sheepdog Club of America, Pembroke Welsh Corgi Club of America, Portuguese Water Dog Foundation, Rottweiler Health Foundation

Breed(s): Rottweiler, American Foxhound, Bloodhound, Irish Water Spaniel, Border Collie, Akita, Boxer, Tibetan Terrier, Newfoundland, Sealyham Terrier, Kerry Blue Terrier, Bulldog, Basset Hound, Doberman Pinscher, Labrador Retriever, Dandie Dinmont Terrier, Golden Retriever
Research Program Area: Oncology - Lymphoma
Donate to Support this Research Program Area


Canine lymphoma is the most common blood-based cancer in dogs with an estimated annual incidence of 30/100,000. Chemotherapy induces remission in 75-85% of patients; however, the majority of patients relapse with drug-resistant lymphoma within 8-10 months of diagnosis and most dogs die of their disease shortly thereafter. Cell-based vaccine strategies that stimulate anti-tumor immunity have shown promise in the treatment of many different cancer types including non-Hodgkin's lymphoma (NHL) in humans. In a previous study Dr. Mason developed a cell-based vaccine to induce anti-tumor immunity in dogs with NHL. Initial studies were hopeful as this early vaccine significantly prolonged second remission duration and overall survival, but ultimately the vaccine did not prevent relapse. These early findings suggest that while the lymphoma vaccine stimulated anti-tumor immunity it will require immunological boosting to achieve prolonged cancer-free survival. In the current study, Dr. Mason will optimize her cell-based vaccine approach to induce functional, long lasting tumor-specific immune responses that will prevent relapse and prolong survival in dogs with NHL.


None at this time.

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Get Canine Health News:
Please leave this field empty
American Kennel Club Canine Health Foundation, Inc

8051 Arco Corporate Dr.
Suite 300
Raleigh, NC 27617

Tax ID# 13-3813813


© 2021 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.